1 Min Read
July 20 (Reuters) - Neuren Pharmaceuticals Ltd
* US FDA granted its request for an end-of-phase 2 meeting to discuss remaining development plan for Trofinetide in Rett syndrome Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.